Receptor News and Research

RSS

Drug addiction expert uncovers molecular mechanisms that contribute to addiction resistance

Growing up in West Virginia, Jill Turner saw firsthand the kind of havoc that drug addiction can wreak. "I had a lot of friends who had very promising lives and promising careers ahead of them," the assistant professor in the South Carolina College of Pharmacy says, "but they ended up either overdosing or going to jail for drug-related stuff. It's one of the reasons I went into drug addiction research."

22 Jul 2015

Gene responsible for cancer growth plays unexpected role in prostate cancer

A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.

22 Jul 2015

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

22 Jul 2015

Study shows glitazone antidiabetic drug may reduce risk of Parkinson’s disease

A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to a new study published in PLOS Medicine.

22 Jul 2015

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine.

22 Jul 2015

New genomic fingerprint may predict prostate cancer risk in African American men

African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it. Although there are many reasons that contribute to this health disparity, new research shows that African American men may have a distinctly different type of prostate cancer than European American men, according to new genomic fingerprinting results.

21 Jul 2015

Patients' own genetically engineered immune cells show significant success against multiple myeloma

In recent years, immunotherapy has emerged as a promising treatment for certain cancers. Now this strategy, which uses patients' own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.

21 Jul 2015

Immunocore completes $320 million (£205 million) private financing round

Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced the completion of a US $320 million (GBP £205 million) private financing round.

16 Jul 2015

Canadian researchers discover how HIV evades the body's antiviral responses

A Canadian research team at the IRCM in Montreal, led by molecular virologist Eric A. Cohen, PhD, made a significant discovery on how HIV escapes the body's antiviral responses. The team uncovered how an HIV viral protein known as Vpu tricks the immune system by using its own regulatory process to evade the host's first line of defence.

16 Jul 2015

AnaptysBio announces completion of oversubscribed $40MM Series D financing round

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology, today announced the completion of an oversubscribed $40MM Series D financing round.

15 Jul 2015

Study: Breast cancer survivors experience post-treatment weight gain compared with cancer-free peers

Among women with a family history of breast cancer, those diagnosed with breast cancer gained weight at a greater rate compared with cancer-free women of the same age and menopausal status.

15 Jul 2015

UAB researchers find therapeutic target for treatment of acute spinal cord injuries

UAB researchers have identified a therapeutic target for the treatment of acute spinal cord injuries. According to this research, conducted on mice, the administration of a drug that prevents loss of myelin - the insulating sheath around nerve fibres that allows signals to be transmitted - increases the mobility of the mice after an injury.

15 Jul 2015

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

15 Jul 2015

Wayne State researcher receives $1.9 million grant to improve EPCs-based cell therapy for vascular diseases

Chunying Li, Ph.D., assistant professor in the Wayne State University School of Medicine's Department of Biochemistry and Molecular Biology, has secured his first R01 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to study the role and mechanism of the chemokine receptor CXCR2 in regulating new blood vessel formation, the so-called angiogenesis.

15 Jul 2015

Study examines how low-methionine diet may help improve outcomes in triple-negative breast cancer patients

A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by a targeted antibody treatment, UW Carbone Cancer Center scientists report in a recent publication.

15 Jul 2015

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN N.V. today received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca's IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).

From QIAGEN Manchester Limited 14 Jul 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

Potential molecular link identified between excess fat in the blood and blood vessel recovery in ischemia

The buildup of fat in the blood makes a bad situation worse - it not only raises a person's risk for heart attack or stroke but also impairs the growth of new blood vessels. How excess fat in the blood - a condition known as hyperlipidemia - blocks vessel growth was unclear, but new work by researchers at Temple University School of Medicine shows that a molecule known as caspase-1 plays a central role and that preventing its activity could be the key to building new blood vessels and restoring blood supply to oxygen-starved tissues.

10 Jul 2015

MGH investigators report that medication could augment benefits of bariatric surgery

New findings about the mechanisms involved - or not involved - in the effects of the most common form of bariatric surgery suggest that combining surgery with a specific type of medication could augment the benefits of the procedure. In a report that has been published online in the journal Endocrinology, Massachusetts General Hospital investigators report that the effects of Roux-en-Y gastric bypass (RYGB) do not utilize neurologic pathways controlled by the serotonin 2C receptor.

9 Jul 2015

Progesterone hormone can benefit breast cancer patients

AROUND half of all breast cancer patients could one day benefit from having the cheap and widely-available female hormone progesterone added to their treatment, according to Cancer Research UK funded research published in Nature today (Thursday).

9 Jul 2015

Receptor News and Research

Drug addiction expert uncovers molecular mechanisms that contribute to addiction resistance

Gene responsible for cancer growth plays unexpected role in prostate cancer

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Study shows glitazone antidiabetic drug may reduce risk of Parkinson’s disease

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

New genomic fingerprint may predict prostate cancer risk in African American men

Patients' own genetically engineered immune cells show significant success against multiple myeloma

Immunocore completes $320 million (£205 million) private financing round

Canadian researchers discover how HIV evades the body's antiviral responses

AnaptysBio announces completion of oversubscribed $40MM Series D financing round

Study: Breast cancer survivors experience post-treatment weight gain compared with cancer-free peers

UAB researchers find therapeutic target for treatment of acute spinal cord injuries

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Wayne State researcher receives $1.9 million grant to improve EPCs-based cell therapy for vascular diseases

Study examines how low-methionine diet may help improve outcomes in triple-negative breast cancer patients

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Potential molecular link identified between excess fat in the blood and blood vessel recovery in ischemia

MGH investigators report that medication could augment benefits of bariatric surgery

Progesterone hormone can benefit breast cancer patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News